Morgan Cheatham, at just 29 years old, has taken on a significant role as the new head of health care and life sciences at Breyer Capital, the investment office led by Jim Breyer, known for his early investments in companies like Facebook and Etsy. Cheatham was granted access to a substantial fortune in April with the task of finding the next groundbreaking ideas in health care and life sciences.
Background and Credentials
Cheatham brings a wealth of experience to his new position. Previously at Bessemer Venture Partners, he worked on investments in prominent digital health companies such as Hinge Health, which recently went public, and Abridge, a company specializing in ambient scribing technology. His background in medicine is equally impressive, having completed his medical degree at Brown University in May and starting a combined pediatrics and genetics residency program at Boston Children’s Hospital and Harvard in June.
Advocacy and Expertise
In addition to his investment and medical background, Cheatham is a leading advocate for health artificial intelligence. He collaborates with prestigious organizations such as the New England Journal of Medicine AI and the Coalition for Health AI, further solidifying his expertise in the intersection of health care and technology.
Breyer Capital’s Health Care Portfolio
Breyer Capital’s health care portfolio is already notable, with investments in highly valued companies like Lyra Health and OpenEvidence. With Cheatham at the helm of health care and life sciences investments, the firm is poised to identify and support innovative companies that could transform the industry.
Conclusion
Cheatham’s unique blend of investment acumen, medical knowledge, and advocacy for health AI positions him well to drive significant advancements in health care and life sciences through Breyer Capital’s investment initiatives.
